期刊文献+

包裹多烯紫杉醇PLGA-PEG纳米粒的制备及体外释放度考察 被引量:7

Preparation and in vitro release of docetaxel-loaded PLGA-PEG nanoparticles
下载PDF
导出
摘要 目的制备包裹多烯紫杉醇PLGA-PEG纳米粒(DTX-NPs)并评价其体外释放行为。方法合成高分子聚合物PLGA-PEG-COOH并表征;以其作为载体,复乳溶剂挥发法制备隐形纳米粒;动态光散射粒径仪和透射电镜测定DTX-NPs的粒径分布、zeta电位及表面形态;采用HPLC法测定DTX-NPs的包封率及载药量;以pH 7.4磷酸缓冲盐溶液(PBS)作为释放介质,考察DTX-NPs的体外释放行为。结果 DTX-NPs平均粒径为(138.8±1.01)nm,zeta电位为(-13.74±3.54)mV,包封率(99.41%±0.29%),载药量(2.47±0.02)μg/mg,24 h突释量为49%。结论 DTX-NPs制备工艺简便可控,结果稳定,且其体外释放行为具有缓释性,能够在血液中长时间滞留,具有良好的应用前景,值得进一步研究。 Objective To prepare the docetaxel(DTX)-loaded nanoparticles based on poly(D,L-lactide-co-gly-colide)-block-poly(ethylene glycol)(PLGA-b-PEG-COOH)(DTX-NPs)and to evaluate their in vitro release property.Methods PLGA-PEG was successfully synthesized and double emulsion solvent evaporation technique was used to prepare DTX-NPs.The size distribution,zeta potential,and surface morphology of the prepared DTX-NPs were characterized by dynamic light scattering(DLS) and transmission electron microscopy(TEM);the entrapment efficiency and drug content were investigated by HPLC;and the in vitro release was examined using phosphate buffer solution as the releasing medium.Results The average diameter of DTX-NPs was(138.8±1.01) nm,the zeta potential was(-13.74±3.54) mV,the encapsulation efficiency was(99.91%±0.29%),the drug load was(2.47±0.02) μg/mg,the 24 h drug release was 49%,and the total drug release in 120 h was 95%.Conclusion The present preparation method for DTX-NPs is reliable and simple,and the product is stable and possesses a sustained release character in vitro.It can stay in the blood for a long period and possess a bright future of application.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2011年第3期295-298,共4页 Academic Journal of Second Military Medical University
基金 国家自然科学基金青年项目(30800259)~~
关键词 多烯紫杉醇 纳米粒子 聚乳酸羟基乙酸共聚物 体外释放 docetaxel; nanoparticles; poly(D,L-lactide-co-glycolide); in vitro release;
  • 相关文献

参考文献16

  • 1Yin Y M,Cui F D, Mu C F,Choi M K, Kim J S, Chung S J, et al. Do- cetaxel microemulsion for enhanced oral bioavailability~ Preparation and in vitro and in vim evaluation[J]. J Contr Rel,2009,140:86-94.
  • 2Lortholary A, Maillard P, Delva R, Boisdron Celle M, Perard D,Vernillet L,et al. Docetaxel in combination with 5-fluoroura- cil in patients with metastatic breast cancer previously treated with anthraeycline based chemotherapy: a Phase I ,dose find ing study[J]. Eur J Cancer, 2000,36 : 1773-1780.
  • 3Micha J P,Goldstein B H,Birk C L,Rettenmaier M A,Brown J V Ⅲ. Abraxane in the treatment of ovarian cancer: the absence of hy- persensitivity reactions[J]. Gynecol Oncol, 2006,100 : 437-438.
  • 4Zhang H J,Xia H S,Wang J,Li Y W. High intensity focused ultrasound-responsive release behavior of PLA-b PEG copoly- met micelles[J]. J Contr Rel, 2009,139 : 31-39.
  • 5Yang A S,Yang L,Liu W,Li Z Y,Xu H B,Yang X L. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nano particles: preparation and in vitro valuation[J]. Int J Pharma eeut, 2007,331 : 123-132.
  • 6Liu Y T, Li K,Pan J,Liu B, Feng S S. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel[J]. Biomateri- als,2010(31) :330-338.
  • 7Cheng J J, Teply B A, Sheriff I, Sung J, Luther G, Gu F X, et al. Formulation of functionalized PLGA PEG nanoparticles for in vivo targeted drug delivery[J]. Biomaterials, 2007,28 : 869-876.
  • 8Park J,Fong P M,Lu J,Sung J,Luther G,Gu F X,et al. PEGylated PLGA nanoparticles for the improved delivery of doxoru- bicin[J]. Nanomed Nanotechnol Biol Med,2009,5:410-418.
  • 9Chen H W,Gao J,Lu Y,Kou G,Zhang H,Fan L,et al. Preparation and characterization of PE38KDEL-Ioaded anti-HER2 nanoparticles for targeted cancer therapy[J]. J Contr Rel, 2008,128:209 216.
  • 10Rao B M,Chakraborty A,Srinivasu M K,Devi M L,Kumar P R, Chandrasekhar K B,et al. A stability-indicating HPLC assay method for docetaxel[J]. J Pharmaceut Biomed Anal, 2006,41 :676 681.

同被引文献85

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部